<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schmieder, Roland E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Left Ventricular Remodeling Reduced with Olmesartan in ROADMAP</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">A prespecified analysis of left ventricular hypertrophy (LVH) as evaluated by electrocardiography from the Olmesartan Medoxomil in Diabetes Mellitus study [ROADMAP] showed that olmesartan significantly reduced LV remodeling in patients with type 2 diabetes mellitus, independent of blood pressure, age, and sex.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>